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Neural progenitor cells (NPCs) can repair damaged myelin in neurodegenerative diseases. In this issue
of Immunity, Cao et al. (2011) report that NPCs also produce the cytokine LIF, which suppresses Th17
cell-driven inflammation and autoimmunity by upregulating the protein Socs3.Stem cell-based therapies hold the key to
next-generation treatments for many
debilitating neurodegenerative diseases.
Pluripotent embryonic stem cells (ESCs)
and neural-tissue derived progenitor cells
possess both self-renewal capacity and
the ability to generate neurons or oligo-
dendrocytes, which makes them an
attractive target for cell-based therapies
in neurodegenerative diseases (Pluchino,
et al., 2003). Transplantation of NPCs in
the central nervous system provides a
means by which demyelinated nerve
fibers can be repaired in neuroinflamma-
tory diseases like multiple sclerosis (MS).
With an experimental animal model of
human MS, it was shown that NPCs are
indeed capable of differentiating into
oligodendrocytes and repairing damaged
myelin (Pluchino, et al., 2003). However, in
addition to their ability to repair damaged
myelin, NPCs may also have anti-inflam-
matory properties and therefore suppress
ongoing inflammation by inhibiting proin-
flammatory effector T cells.
Although the etiology of multiple scle-
rosis is not well understood, it is clear
that myelin sheath of the white matter of
theCNS is the target of immune attack, re-
sulting in inflammation and subsequent
demyelination, which leads to axonal
resection and neuronal degeneration.
Self-reactive CD4+ T helper (Th) and
CD8+ T cells that produce proinflamma-
tory cytokines play a critical role in in-
ducing the disease. Naive CD4+ T cells
differentiate into different effector T cells
subsets upon activation. These effector
T cells have been classified into Th1,
Th2, and Th17 cells, on the basis of
their cytokines and effector functions.
Emerging evidence indicates that proin-
flammatory Th1 cells, which produce
interferon-g (IFN-g), interleukin-2 (IL-2),156 Immunity 35, August 26, 2011 ª2011 Elsand lymphotoxin b, and Th17 cells, which
produce IL-17A, IL-17F, and IL-22, play
a key role in inducing the disease (Korn
et al., 2009; Kuchroo et al., 2002). The crit-
ical role of Th17 cells has been further
demonstrated in a number of autoimmune
diseases including experimental autoim-
mune encephalomyelitis (EAE), an animal
of model of human MS (Korn et al.,
2009). Genetic deficiencies of Th17 asso-
ciated molecules such as RoRgt, STAT3,
IL-23p19 and IL-23R lead to almost
complete resistance to development of
EAE (Korn et al., 2009). Based on these
observations, IL-17-producing Th17 cells
have been proposed to play a critical role
in initiating tissue inflammation in EAE
and many other autoimmune diseases.
In addition to differentiating into oligo-
dendrocytes in the areas of demyelin-
ation, NPC treatment has also been
shown to control tissue inflammation in
EAE, suggesting that NPCs might sup-
press the effector functions of self-reac-
tive T cells (Einstein et al., 2003). How-
ever, it was not clear until now as to how
NPCs dampen T cell response and regu-
late tissue inflammation in EAE. In this
issue of Immunity, Cao et al. (2011) report
the underlying mechanism by which
NPCs control tissue inflammation during
EAE (Figure 1). This paper illustrates that
NPCs produce a number of anti-inflam-
matory cytokines including LIF, which
normally plays a role in neurogenesis.
However, this paper (Cao et al., 2011)
reports that LIF ameliorates EAE by selec-
tively and specifically suppressing the
development of Th17 cells. LIF belongs
to the IL-6 family of cytokines and signals
via a LIF receptor together with gp130,
a common receptor chain that is also
used by IL-6 and other IL-6 family cyto-
kines. We and others have previouslyevier Inc.shown that IL-6 together with IL-1 and
transforming growth factor beta (TGF-b)
induce Th17 cell differentiation (Bettelli
et al., 2006; Veldhoen et al., 2006), and
in fact IL-6 acts as a pivot that dictates
the balance of whether a naive T cell
would become a effector Th17 cells or
regulatory FoxP3+ T cell (Bettelli et al.,
2006).
The idea that NPCs must suppress
T cell response in the peripheral immune
compartment came from the observation
that whereas a single intravenous injec-
tion of NPCs ameliorated EAE, immunized
mice treated with NPCs did not show any
infiltration of NPCs into their CNS (Cao
et al., 2011). In fact, the vast majority of
NPCs were found to be present in the
secondary lymphoid organs (lymph nodes
and spleen). This implies that NPCs may
not simply inhibit EAE by differentiating
into oligodendrocytes and thus repairing
the damaged myelin sheath, but must
also suppress effector T cells in the
peripheral immune compartments. This
was further supported by the observation
that administering irradiated NPCs, which
had lost their ability to differentiate into
oligodendrocytes, could still suppress
EAE. This raised the issue of whether
NPCs-derived soluble factors could sup-
press EAE by inhibiting effector T cells
responses (Cao et al., 2011).
To identify the soluble factor(s) pro-
duced by NPCs that inhibit proinflamma-
tory effector T cells, Cao et al. screened
a known panel of cytokines and neurotro-
pins produced by NPCs. Among other
factors produced by NPCs, Cao et al.
found that fully differentiated NPCs
predominantly produce LIF, which in-
hibited differentiation of Th17 cells—and
neutralization of LIF by a LIF antibody
restored IL-17 production (Cao et al.,
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Figure 1. Leukemia Inhibitory Factor Antagonizes the Development
of Th17 Cells
NPC-derived leukemia inhibitory factor (LIF) induces ERK-1- and ERK-2-
dependent expression of Socs3. Overexpression of Socs3 by leukemia inhib-
itory factor attenuates the activation of STAT3, which in turn suppresses IL-17
production.
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of the NPCs supernatant with
LIF antibody abrogated the
protective effect of NPC-
derived supernatant in EAE,
with the reappearance of
Th17 cells in the periphery
and CNS of the affected
mice. Consistent with this
observation, in vivo adminis-
tration of LIF inhibited the
development of EAE with
a commensurate decrease in
Th17 cells (Cao et al., 2011).
Cao et al. showed that LIF-
receptor is actively expressed
on differentiated Th17 cells,
which makes them respon-
sive to LIF dependent inhibi-
tion. From these data, it is
clear that the two familymembers, IL-6 and LIF, have opposite
effects on Th17 cell development (Bettelli
et al., 2006; Cao et al., 2011).
During Th17 cell differentiation, IL-6
induces phosphorylation of STAT3
(pSTAT3) that binds to promoter elements
of the gene encoding RoRgt, a transcrip-
tion factor that induces development of
Th17 cells (Durant et al., 2011). The critical
role of STAT3 in Th17 cell development
has also been supported by a number of
experimental observations. For example,
conditional deficiency of STAT3 in CD4+
T cells abrogated the development of
Th17 cells, and these mice were highly
resistant to EAE (Liu et al., 2008). Because
LIF binding to LIFR regulates proximal
signaling events during Th17 cell develop-
ment, Cao et al. found that LIF selectively
inhibited STAT3 activation without af-
fecting STAT1 and STAT6 activation, the
transcription factors that are essential
for the development of Th1 and Th2
cells, respectively. LIF treatment induced
Socs3 expression both in vitro and in vivo,which is known to inhibit generation and
activation of pSTAT3. Inhibition of Socs3
expression by introduction of Socs3-
specific siRNA abrogated the inhibitory
effects of LIF on Th17 cell development.
The authors further showed that LIF-
induced Socs3 expression was depen-
dent on ERK-1 and ERK-2 activation as
a selective inhibitor of MEK-ERK path-
way inhibited LIF-induced Socs3 expres-
sion. Taken together, these observations
provide the evidence that LIF-induced
inhibition of Th17 cells is dependent on
ERK-1- and ERK-2-induced expression
of Socs3, which is a critical negative
regulator of Stat3 activation (Figure 1).
Cao et al. further translated their findings
to human Th17 cells. Similarly to mouse
NPCs, human NPCs also produce large
amount of LIF in their culture supernatant,
which inhibited the development of
human Th17 cells in Socs3-dependent
manner (Cao et al., 2011). Furthermore,
LIF treatment inhibited the production of
IL-17 in CD4+ T cells from MS patients.Immunity 35, August 26These observations add a
new dimension to stem cell-
based therapy for inflamma-
tory neurodegenerative dis-
eases. TheNPCsmaynot only
suppress CNS autoimmune
demyelinating disease by
differentiating into oligoden-
drocytes and repairing injured
myelin sheath but also by in-
hibiting proinflammatory Th17
cells. In addition, these obser-
vations highlight LIF as an
interesting target for treating
many autoimmune diseases
including multiple sclerosis.REFERENCES
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